No Data
No Data
Express News | Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024
Express News | Spyre to Present Interim Spy001 Data by Year-End 2024
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics Down Nearly 20%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk
Spyre Therapeutics, Inc (SYRE) is currently at $25.26, down $6.25 or 19.83% --Would be lowest close since Feb. 27, 2024, when it closed at $24.91 --Onpace for largest percent decrease since June 21,
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.4%
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...